Hitag Biotechnology is dedicated to develop recombinant proteins and immunogens without the need for adjuvants, by using two patented platforms.
Fh8 r-PPure – this platform allows you to produce soluble and highly pure recombinant proteins. This platform relies in the smallest solubilisation tag, 8 kDa, which has affinity to hydrophobic purification colums.
H VerImmune Ligand –this platform allows you to combine a high immunogenic peptide with a recombinant antigen. The immunisation procedure of this recombinant immunogen does not require coadministration of adjuvant.
Hitag Biotechnology, Lda
Parque Tecnológico de Cantanhede, N4 L4
3060 -197 Cantanhede, Portugal
E-mail: info@hitag.pt
